Evidence map›Paper›PMID 29254159›Full record

ArticleOncotarget2017

Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.

Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller, Stefanie Krassnig, Margit Gogg-Kamerer, Nadine Gantenbein, Anna M Toeglhofer, Christina Wodlej, Helmut Bergler, Brigitte Pertschy and 16 more

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 3 countries.

Nicole Golob-SchwarzlInstitute of Pathology, Medical University of Graz, Graz, Austria.
Caroline SchweigerInstitute of Pathology, Medical University of Graz, Graz, Austria.
Carina KollerInstitute of Pathology, Medical University of Graz, Graz, Austria.
Stefanie KrassnigInstitute of Pathology, Medical University of Graz, Graz, Austria.
Margit Gogg-KamererInstitute of Pathology, Medical University of Graz, Graz, Austria.
Nadine GantenbeinInstitute of Pathology, Medical University of Graz, Graz, Austria.
Anna M ToeglhoferInstitute of Pathology, Medical University of Graz, Graz, Austria.
Christina WodlejInstitute of Pathology, Medical University of Graz, Graz, Austria.
Helmut BerglerInstitute of Molecular Biosciences, Karl-Franzens-University of Graz, Graz, Austria.
Brigitte PertschyInstitute of Molecular Biosciences, Karl-Franzens-University of Graz, Graz, Austria.
Stefan UranitschDepartment of Surgery, Hospital Brothers of Charity Graz, Graz, Austria.
Magdalena HolterInstitute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
Amin El-HeliebiInstitute of Cell Biology, Histology and Embryology, Medical University Graz, Graz, Austria.
Julia FuchsInstitute of Cell Biology, Histology and Embryology, Medical University Graz, Graz, Austria.
Andreas PunschartDepartment of Surgery, Medical University of Graz, Graz, Austria.
Philipp StieglerDepartment of Surgery, Medical University of Graz, Graz, Austria.
Marlen KeilExperimental Pharmacology & Oncology Berlin GmbH-Berlin-Buch, Berlin, Germany.
Jens HoffmannExperimental Pharmacology & Oncology Berlin GmbH-Berlin-Buch, Berlin, Germany.
David HendersonBayer AG, Berlin, Germany.
Hans LehrachMax Planck Institute for Molecular Genetics, Berlin, Germany.
Christoph ReinhardEli Lilly & Company, Indianapolis, USA.
Christian RegenbrechtCpo - cellular phenomics & oncology Berlin-Buch GmbH, Berlin, Germany.
Rudolf SchichoInstitute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.
Peter FickertDivision of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
Sigurd LaxDepartment of Pathology, Hospital Graz South-West, Austria.
Johannes HaybaeckInstitute of Pathology, Medical University of Graz, Graz, Austria.
Medical University of Graz · ATCenter For Biomarker Research In Medicine · ATUniversity of Graz · ATBayer (Germany) · DEEli Lilly (United States) · USGraz University Hospital · ATHospital of the Brothers of St. John of God · ATMax Planck Institute for Molecular Genetics · DE

Funding

Austrian Science Fund FWF KLI 521Austrian Science Fund FWF P 25633
6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most common cause of cancer related death worldwide. Furthermore, with more than 1.2 million cases registered per year, it constitutes the third most frequent diagnosed cancer entity worldwide. Deregulation of protein synthesis has received considerable attention as a major step in cancer development and progression. Eukaryotic translation initiation factors (eIFs) are involved in the regulation of protein synthesis and are functionally linked to the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. The identification of factors accounting for colorectal carcinoma (CRC) development is a major gap in the field. Besides the importance of eIF3 subunits and the eIF4 complex, eIF1, eIF5 and eIF6 were found to be altered in primary and metastatic CRC. We observed significant difference in the expression profile between low and high grade CRC. eIF1, eIF5 and eIF6 are involved in translational control in CRC. Our findings also indicate a probable clinical impact when separating them into low and high grade colon and rectum carcinoma. eIF and mTOR expression were analysed on protein and mRNA level in primary low and high grade colon carcinoma (CC) and rectum carcinoma (RC) samples in comparison to non-neoplastic tissue without any disease-related pathology. To assess the therapeutic potential of targeting eIF1, eIF5 and eIF6 siRNA knockdown in HCT116 and HT29 cells was performed. We evaluated the eIF knockdown efficacy on protein and mRNA level and investigated proliferation, apoptosis, invasion, as well as colony forming and polysome associated fractions. These results indicate that eIFs, in particular eIF1, eIF5 and eIF6 play a major role in translational control in colon and rectum cancer.

Indexed as

colorectal carcinomaeukaryotic translation initiation factorsliver metastasesPI3K/AKT/mTOR pathway

Identifiers

PMID29254159
PMCPMC5731869
OpenAlexW2751117865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.